CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2005--Alkermes, Inc., (Nasdaq: ALKS) will host a conference call at 4:30pm EST on Thursday, February 3, 2005 to discuss the Company's financial results for its third quarter of fiscal 2005. Management will review the quarter and provide an update on the Company.
The conference call may be accessed by dialing 1-866-818-1393 for domestic callers and 1-703-639-1377 for international callers. The conference call ID number is 642756. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Tuesday, February 8, 2005 at 5:00pm EST.
A replay of the conference call will be available from 7:30pm EST on February 3, 2005 through 5:00pm EST on February 8, 2005, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 642756.
Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, Risperdal Consta(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag, a division of Johnson & Johnson. The Company's lead proprietary product candidate, Vivitrex(R) ((naltrexone) long-acting injection), is a once-a-month injection for the treatment of alcohol dependence. Alkermes has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technology and expertise. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.
For more information on Alkermes, please visit www.alkermes.com.
CONTACT:
Alkermes, Inc.
Jaren Madden
617-583-6402